Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CERO

CERo Therapeutics Holdings Inc

Nov 21 • 04:00PM ET

0.2479

Dollar change -0.0009
Percentage change -0.36	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	34.92%	Shs Outstand	51.35M	Perf Week	32.43%
Market Cap	37.26M	Forward P/E	-	EPS next Y	-	Insider Trans	-6.72%	Shs Float	33.42M	Perf Month	182.35%
Income	-9.26M	PEG	-	EPS next Q	-	Inst Own	4.24%	Short Float	4.79%	Perf Quarter	78.09%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.03	Perf Half Y	-73.63%
Book/sh	-0.04	P/B	-	EPS next Y	-	ROA	-108.70%	Short Interest	1.60M	Perf Year	-97.73%
Cash/sh	0.02	P/C	11.03	EPS next 5Y	-	ROE	-4090.08%	52W Range	0.06 - 12.80	Perf YTD	-97.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-98.06%	Beta	0.20
Dividend TTM	-	Quick Ratio	0.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	289.78%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	0.39	EPS Y/Y TTM	-17.53%	Oper. Margin	0.00%	RSI (14)	64.32	Volatility	31.74% 21.52%
Employees	9	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-61.17%	Payout	-	Rel Volume	0.24	Prev Close	0.25
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	62.80M	Price	0.25
SMA20	65.94%	SMA50	114.19%	SMA200	-75.27%	Trades		Volume	14,891,016	Change	-0.36%

Nov-15-24 08:45AM	CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia (GlobeNewswire) +52.40%
Nov-11-24 08:15AM	CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity (GlobeNewswire) +180.00%
Oct-21-24 09:00AM	CERo Therapeutics, Inc. Provides Corporate Update (GlobeNewswire)
Oct-02-24 09:15AM	CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer (GlobeNewswire) -14.23%
Sep-25-24 09:17AM	CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 (GlobeNewswire) +6.72%
08:00AM	Loading…
Jul-08-24 08:00AM	CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 (GlobeNewswire) -18.46%
Jun-13-24 08:15AM	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 (GlobeNewswire) -48.86%
Jun-06-24 10:15AM	Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy (ACCESSWIRE) -16.47%
08:00AM	CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 (GlobeNewswire)
May-15-24 08:00AM	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders (GlobeNewswire)
Apr-30-24 09:00AM	CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes (GlobeNewswire)
Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire) -16.24%
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SLOAN STUART M	10% Owner	Sep 25 '24	Sale	0.10	532,486	55,538	21,067,956	Nov 20 04:04 PM
YK Bioventures Opportunities G	10% Owner	Oct 10 '24	Sale	0.10	3,250,000	325,000	22,620,783	Nov 14 08:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc

Upgrade your FINVIZ experience